Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities

Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, JapanObjective: Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Okazaki K, Makinodan M, Yamamuro K, Takata T, Kishimoto T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	methamphetamine methamphetamine-induced psychosis intellectual disabilities blonanserin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ef891a952396438a8f6f9cb5c5412e2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ef891a952396438a8f6f9cb5c5412e2b
record_format	dspace
spelling	oai:doaj.org-article:ef891a952396438a8f6f9cb5c5412e2b2021-12-02T06:32:05ZBlonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities1178-2021https://doaj.org/article/ef891a952396438a8f6f9cb5c5412e2b2016-12-01T00:00:00Zhttps://www.dovepress.com/blonanserin-treatment-in-patients-with-methamphetamine-induced-psychos-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, JapanObjective: Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious social dysfunction. MA use causes frequent psychotic symptoms, which can be treated with antipsychotics. However, people with intellectual disabilities (ID) are vulnerable to adverse effects resulting from treatment with antipsychotic medications.Method: We report two cases of MA-induced psychosis (MAP) in patients with ID who were treated with the antipsychotic blonanserin.Results: In both the cases presented, symptoms of psychosis were improved by switching medications from other antipsychotic drugs to blonanserin. Despite the presence of ID in these patients, no significant adverse effects, such as sedation, were detected after treatment with blonanserin.Conclusion: Blonanserin may be an effective and well-tolerated pharmacotherapeutical treatment for patients with MAP comorbid with ID. However, further work is necessary to validate this claim.Keywords: methamphetamine, methamphetamine-induced psychosis, intellectual disabilities, blonanserinOkazaki KMakinodan MYamamuro KTakata TKishimoto TDove Medical Pressarticlemethamphetaminemethamphetamine-induced psychosisintellectual disabilitiesblonanserinNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 3195-3198 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	methamphetamine methamphetamine-induced psychosis intellectual disabilities blonanserin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	methamphetamine methamphetamine-induced psychosis intellectual disabilities blonanserin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Okazaki K Makinodan M Yamamuro K Takata T Kishimoto T Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
description	Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, JapanObjective: Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious social dysfunction. MA use causes frequent psychotic symptoms, which can be treated with antipsychotics. However, people with intellectual disabilities (ID) are vulnerable to adverse effects resulting from treatment with antipsychotic medications.Method: We report two cases of MA-induced psychosis (MAP) in patients with ID who were treated with the antipsychotic blonanserin.Results: In both the cases presented, symptoms of psychosis were improved by switching medications from other antipsychotic drugs to blonanserin. Despite the presence of ID in these patients, no significant adverse effects, such as sedation, were detected after treatment with blonanserin.Conclusion: Blonanserin may be an effective and well-tolerated pharmacotherapeutical treatment for patients with MAP comorbid with ID. However, further work is necessary to validate this claim.Keywords: methamphetamine, methamphetamine-induced psychosis, intellectual disabilities, blonanserin
format	article
author	Okazaki K Makinodan M Yamamuro K Takata T Kishimoto T
author_facet	Okazaki K Makinodan M Yamamuro K Takata T Kishimoto T
author_sort	Okazaki K
title	Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
title_short	Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
title_full	Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
title_fullStr	Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
title_full_unstemmed	Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
title_sort	blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ef891a952396438a8f6f9cb5c5412e2b
work_keys_str_mv	AT okazakik blonanserintreatmentinpatientswithmethamphetamineinducedpsychosiscomorbidwithintellectualdisabilities AT makinodanm blonanserintreatmentinpatientswithmethamphetamineinducedpsychosiscomorbidwithintellectualdisabilities AT yamamurok blonanserintreatmentinpatientswithmethamphetamineinducedpsychosiscomorbidwithintellectualdisabilities AT takatat blonanserintreatmentinpatientswithmethamphetamineinducedpsychosiscomorbidwithintellectualdisabilities AT kishimotot blonanserintreatmentinpatientswithmethamphetamineinducedpsychosiscomorbidwithintellectualdisabilities
_version_	1718399910036897792

Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities

Ejemplares similares